Connor Iapoce

Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.

SGLT2 inhibitors show a reduced risk of retinopathy compared with DPP-4 inhibitors, pioglitazone, and sulfonylureas among patients with type 2 diabetes.

Weight cycling could lead to a relative loss of fat-free mass in people living with overweight and obesity at high risk of type 2 diabetes.

A review and meta-analysis of 29 studies found systolic blood pressure significantly decreased in the semaglutide group compared with placebo or other active controls.

In the Dapa-ON trial, the careful selection of people with T1D and the implementation of strategies to reduce the risk of DKA were associated with dapagliflozin's appropriate safety profile.

The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team.

Microbiota-based interventions may be a novel strategy to benefit the mitigation of chronic kidney disease advancement.

Continuous glucose monitoring metrics showed that patients with burnt-out diabetes and end-stage kidney disease experience significant undiagnosed hyperglycemia.

Announced by Glaukos on December 14, 2023, the prostaglandin analog approval is indicated for the reduction of intraocular pressure among patients with ocular hypertension or open-angle glaucoma.

Global incidence of T1D among children and adolescents <20 years old is substantial, but these rates exhibited significant variability by country, region, and age group.

Patients with T1D diabetic retinopathy showed a longer duration of diabetes and increased age, compared to those without retinopathy.

Results from the MOMPOD RCT indicate metformin added to insulin did not reduce the frequency of a composite adverse neonatal outcome in pregnant adults with diabetes.

The phase 3 STAND study contrasts from the phase 2 SUSTAIN study results, highlighting the absence of superiority of crizanlizumab over placebo on key efficacy endpoints.

Two experts describe the correlation between the severity of arginine deficiency and worse clinical outcomes among hospitalized children with sickle cell disease experiencing vaso-occlusive pain episodes.

Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?

Increases in the working-age population during the 30-year period may have contributed to the global burden of visual impairment

Positive topline results from the phase 2 trial indicate EYP-1901 exhibited statistical non-inferiority in BCVA to aflibercept, with a favorable safety profile.

The review emphasized the importance of therapies that provide sustained visual outcomes, given the increasing incidence of nAMD among aging adults.

Real-world data shows extended intervals with both brolucizumab alone or alternating anti-VEGF treatment regimens after 12 and 18 months in nAMD eyes.

Pharmacokinetic exposure of the biosimilar insulin and reference product showed similarity, supporting the interchangeability between the two insulin aspart products.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our November 2023 month-in-review features a trio of FDA news, important updates to the GA pipeline, and insight into disparities in eye care.

Higher vitamin B1 intake levels were associated with lower prevalence of late AMD in an analysis of NHANES data from 2005 to 2008.

A treat-and-extend regimen with aflibercept showed both anatomical and functional improvements for patients with nAMD and PCV during a two-year study.

Metformin use was associated with a reduced likelihood of any AMD and dry AMD in a sample of patients without diabetes.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.

Nationwide data from Korea suggest abstinence from alcohol led to lower risks of clinical outcomes among patients with newly diagnosed open-angle glaucoma.

Outlook Therapeutics plans to resubmit the BLA for ophthalmic bevacizumab by the end of 2024, pending the successful completion of a required additional trial.